Trial · NCT06338202
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in New York Heart Association (NYHA) functional class following mavacamten treatment initiation | Up to 1.5 years | * Proportion of patients in each New York Heart Association (NYHA) functional class following mavacamten treatment initiation * Proportion of patients with a reduction of ≥1 New York Heart Association (NYHA) functional class following mavacamten treatment initiation |
| Secondary | Change in left ventricular outflow tract (LVOT) with Valsalva maneuver (vLVOT) gradient following mavacamten treatment initiation | Up to 1.5 years | |
| Secondary | Proportion of patients with left ventricular outflow tract (LVOT) with Valsalva maneuver gradient (vLVOT) < 20mmHg following mavacamten treatment initiation | Up to 1.5 years | |
| Secondary | Age | Baseline | |
| Secondary | Sex at birth | Baseline | |
| Secondary | Ethnicity | Baseline | |
| Secondary | Employment status | Baseline | |
| Secondary | Body mass index (BMI) | Baseline | |
| Secondary | Obstructive hypertrophic cardiomyopathy (oHCM) disease duration | Baseline | |
| Secondary | Proportion of patients in each New York Heart Association (NYHA) functional class II and III | Baseline | |
| Secondary | Left ventricular outflow tract (LVOT) with Valsalva maneuver (vLVOT) gradient | Baseline | |
| Secondary | Left ventricular ejection fraction by 2D echocardiogram (LVEFb) | Baseline | |
| Secondary | Mavacamten dose regimen | Up to 1.5 years | |
| Secondary | Proportion of patients who discontinued mavacamten | Up to 1.5 years | |
| Secondary | Duration of treatment prior to mavacamten discontinuation | Up to 1.5 years | |
| Secondary | Left ventricular ejection fraction by 2D echocardiogram (LVEF) at the time of mavacamten treatment discontinuation | Up to 1.5 years | |
| Secondary | Proportion of patients with left ventricular ejection fraction by 2D echocardiogram (LVEF) < 50% at the time of mavacamten treatment discontinuation | Up to 1.5 years | |
| Secondary | Reason for discontinuing mavacamten treatment | Up to 1.5 years | |
| Secondary | Functional assessment schedule | Up to 1.5 years | * Proportion of patients who undergo left ventricular outflow tract with Valsalva maneuver gradient (vLVOT) functional assessment * Proportion of patients who undergo left ventricular ejection fraction (LVEF) assessment |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06338202/registered